WanYong Feng, PhD

Dr. WanYong Feng brings 26 years of industrial experience in drug metabolism, pharmacokinetics, toxicokinetics, exploratory toxicity, and bioanalytical chemistry. His work spans ADME/PK/TK/eTox evaluation, lead optimization, IND-enabling studies, and Phase I clinical development. He has authored 45 publications and served in reviewer and editorial advisory roles.

▪ 26 years of DMPK and bioanalysis experience

▪ Expertise across ADME, PK/TK, eTox, and IND-enabling studies

▪ Reviewer and editorial advisory board member

▪ Ph.D., Chinese Academy of Sciences

▪ Industry background: Chiron, Novartis, Bridge Labs, Wuxi AppTec, Amphastar, Dart Neuroscience, BioDuro